1-20 of 20
Anne Pradines
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB094: Assessment of minimal residual disease in lung cancer patients treated with osimertinib using liquid biopsy

Celia Delahaye, Anne Casanova, Estelle Clermont-Tarenchon, Aurelia Doussine, Juan-Pablo Cerapio, Anaïs Anton, Emma Devienne, Vincent Dongay, Julie Milia, Gilles Favre, Olivier Calvayrac, Anne Pradines, Julien Mazieres
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB094.
https://doi.org/10.1158/1538-7445.AM2024-LB094
Published: 05 April 2024
View article titled, Abstract LB094: Assessment of minimal residual disease in lung cancer patients treated with osimertinib using liquid biopsy
Journal Articles

Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

Caroline Bailleux, Thomas Bachelot, Francois-Clement Bidard, Anne-Claire Hardy-Bessard, Ivan Bièche, Anne Pradines, Florian Clatot, thibault DE LA MOTTE ROUGE, Jean-Luc Canon, Barbara Pistilli, Kyle Chang, Katie J. Quinn, Heather L. Gustafson, Florence Dalenc, Cyril Foa, Hanifa Ammarguellat, Chantal Bernard-Marty, Brigitte Lucas, Sophie Barthier, Fabrice Lorchel, Olivier Gisserot, Laurent Arnould, Marjorie Mauduit, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, Fabrice Andre
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD17-02.
https://doi.org/10.1158/1538-7445.SABCS22-PD17-02
Published: 01 March 2023
View article titled, Abstract PD17-02: ctDNA Molecular Response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer
Journal Articles

Abstract LB080: Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC

Sarah Figarol, Célia Delahaye, Rémi Gence, Raghda Asslan, Sandra Pagano, Jacques Colinge, Jean-Philippe Villemin, Antonio Maraver, Isabelle Lajoie-Mazenc, Estelle Clermont, Anne Casanova, Anne Pradines, Julien Mazières, Olivier Calvayrac, Gilles Favre
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB080.
https://doi.org/10.1158/1538-7445.AM2022-LB080
Published: 15 June 2022
View article titled, Abstract LB080: Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC
Journal Articles

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

François-Clément Bidard, Anne-Claire Hardy-Bessard, Thomas Bachelot, Jean-Yves Pierga, Jean-Luc Canon, Florian Clatot, Fabrice Andre, Thibault De La Motte Rouge, Barbara Pistilli, Florence Dalenc, Nadine Dohollou, Olivier Arsene, Thierry Petit, Cécilia Riedl, François Morvan, Adina Marti, Emma Lachaier, Mihaela Achille, Michel Gozy, Anne Escande, Dominique Mille, Fanny Trouboul, Laurent Arnould, Ivan Bieche, Anne Pradines, Jerome Lemonnier, Frederique Berger, Suzette Delaloge
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS3-05.
https://doi.org/10.1158/1538-7445.SABCS21-GS3-05
Published: 15 February 2022
View article titled, Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating <em>ESR1</em> mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
Journal Articles

Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS

Céline Callens, François-Clément Bidard, Anais Curto-Taribo, Olfa Trabelsi-Grati, Samia Melaabi, Suzette Delaloge, Anne-Claire Hardy-Bessard, Thomas Bachelot, Florian Clatot, Thibault De La Motte Rouge, Jean-Luc Canon, Laurent Arnould, Fabrice André, Sandrine Marques, Marc-Henri Stern, Jean-Yves Pierga, Anne-Vincent Salomon, Emmanuelle Jeannot, Frederique Berger, Ivan Bieche, Anne Pradines
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-07-01.
https://doi.org/10.1158/1538-7445.SABCS21-P1-07-01
Published: 15 February 2022
View article titled, Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS
Journal Articles

Abstract CT189: Characterization of ESR1 mutations at metastatic relapse and outcome under first line aromatase inhibitor and palbociclib in the PADA-1 trial

Anne Pradines, Céline Callens, Aurélia Doussine, Ivan Bièche, Jérôme Lemonnier, Marjorie Mauduit, Thomas Bachelot, Florence Dalenc, Alain Lortholary, Barbara Pistilli, Thibault De La Motte Rouge, Renaud Sabatier, Jean-Marc Ferrero, Sylvain Ladoire, Frédérique Berger, François-Clément Bidard
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT189.
https://doi.org/10.1158/1538-7445.AM2021-CT189
Published: 01 July 2021
View article titled, Abstract CT189: Characterization of <em>ESR1</em> mutations at metastatic relapse and outcome under first line aromatase inhibitor and palbociclib in the PADA-1 trial
Journal Articles

Abstract P2-18-06: Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study

Vincent Nicolaï, Julia Gilhodes, Jean Louis Lacaze, Mony Ung, Eleonora De Maio, Raphaelle Duprez-Paumier, Charlotte Vaysse, Thomas Filleron, Eva Jouve, Gabrielles Selmes, Camille Franchet, Carole Massabeau, Cyprian Chira, Francoise Izar, Henri Roché, Anne Pradines, Florence Dalenc
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-18-06.
https://doi.org/10.1158/1538-7445.SABCS19-P2-18-06
Published: 15 February 2020
View article titled, Abstract P2-18-06: Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study
Journal Articles

Abstract P5-11-22: Clinical and biological efficacy of first line AI and palbociclib in ER+ HER2- MBC with detectable circulating ESR1 mutation prior to treatment initiation

François-Clément Bidard, Céline Callens, Florence Dalenc, Barbara Pistilli, Thibault de la Motte Rouge, Florian Clatot, Véronique D'Hondt, Luis Teixeira, Sibille Everhard, Hélène Vegas, Jérôme Lemonnier, Ivan Bieche, Anne Pradines, Jean-François Paitel, Dominique Spaeth, Jean-Luc Canon, Isabelle Moullet, Jean-Yves Pierga, Frédérique Berger, Thomas Bachelot, Suzette Delaloge
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-11-22.
https://doi.org/10.1158/1538-7445.SABCS19-P5-11-22
Published: 15 February 2020
View article titled, Abstract P5-11-22: Clinical and biological efficacy of first line AI and palbociclib in ER+ HER2- MBC with detectable circulating <em>ESR1</em> mutation prior to treatment initiation
Journal Articles

Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas

Sandra Ortiz-Cuaran, Julien Mazières, Aurélie Swalduz, Washington René Chumbi Flores, Yohan Loriot, Virginie Westeel, Anne Pradines, Claire Tissot, Christelle Clement Duchene, Christine Raynaud, Xavier Quantin, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Séverine Neymarc, Virginie Avrillon, Solène Marteau, Séverine Martinez, Gilles Clapisson, Nathalie Girerd-Chambaz, Celine Mahier, Nathalie Hoog-Labouret, Frank de Kievit, Karen Howarth, Emma Green, Clive Morris, Maurice Pérol, Jean-Yves Blay, Pierre Saintingy
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1841.
https://doi.org/10.1158/1538-7445.AM2018-1841
Published: 01 July 2018
View article titled, Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Journal Articles

Abstract 2753: Translation to the clinic of EVT801: A novel immune-oncology agent for addressing innate-driven immunosuppression into the tumor microenvironment and expanding patient population responding to immune checkpoint therapies

Pierre Fons, Michael Esquerre, Julien Mazieres, Philippe Rochaix, Anne Gomez-Brouchet, Antoine Alam, Florie Bertrand, Celine Poussereau-Pomie, Jerome Meneyrol, Anne Pradines, janick selves, Isabelle Rouquette, Isabelle Blanc, Francoise Bono, Donogh P. O'Brien, Michael Paillasse, Joanna Lisztwan, Mark Whittaker
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2753.
https://doi.org/10.1158/1538-7445.AM2018-2753
Published: 01 July 2018
View article titled, Abstract 2753: Translation to the clinic of EVT801: A novel immune-oncology agent for addressing innate-driven immunosuppression into the tumor microenvironment and expanding patient population responding to immune checkpoint therapies
Journal Articles

Abstract P4-07-08: Circulating miRNAs as surrogate markers for hormonosensibility in patients with hormone receptor-positive metastatic breast cancer? A pilot study

Florence Dalenc, Monia Ouali, Thomas Filleron, Laurence Gladieff, Henri Roché, Jean-Louis Lacaze, William Jacot, Anna Durigova, Anne Pradines, Pauline Bringer, Magali Farella, Gilles Favre
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-07-08.
https://doi.org/10.1158/1538-7445.SABCS14-P4-07-08
Published: 01 May 2015
View article titled, Abstract P4-07-08: Circulating miRNAs as surrogate markers for hormonosensibility in patients with hormone receptor-positive metastatic breast cancer? A pilot study
Journal Articles

Abstract 1865: Circulating microRNA expression profile: miR-1246 and miR-185 profile as a novel diagnostic biomarker for melanoma

Virginie Armand-Labit, Nicolas Meyer, Anne Casanova, Stephane Verdun, Marie Bruillard, Gilles Favre, Anne Pradines
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1865.
https://doi.org/10.1158/1538-7445.AM2014-1865
Published: 01 October 2014
View article titled, Abstract 1865: Circulating microRNA expression profile: miR-1246 and miR-185 profile as a novel diagnostic biomarker for melanoma
Journal Articles

Abstract 3401: Vemurafenib-induced RhoB expression leads to melanoma cell resistance.

Audrey Delmas, Julia Cherier, Claire Medale-Giamarchi, Anne Pradines, Gilles Favre
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3401.
https://doi.org/10.1158/1538-7445.AM2013-3401
Published: 15 April 2013
View article titled, Abstract 3401: Vemurafenib-induced RhoB expression leads to melanoma cell resistance.
Journal Articles

Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1

Emilie Bousquet, Julien Mazières, Maud Privat, Virginie Rizzati, Anne Casanova, Adeline Ledoux, Eliane Mery, Bettina Couderc, Gilles Favre, Anne Pradines
Journal: Cancer Research
Cancer Res (2009) 69 (15): 6092–6099.
https://doi.org/10.1158/0008-5472.CAN-08-4147
Published: 29 July 2009
View article titled, Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1
Open the PDF for Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1 in another window
Includes: Supplementary data
Journal Articles

Abstract #2383: RhoB controls estrogen receptor alpha (ER alpha) expression in mammary cell models

Sophie Doisneau-Sixou, Elise Meunier, Emilie Malissein, Georges Prendergast, Emilie bousquet, Anne Pradines, Gilles Favre, Florence Dalenc
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2383.
Published: 01 May 2009
View article titled, Abstract #2383: RhoB controls estrogen receptor alpha (ER alpha) expression in mammary cell models
Journal Articles

Abstract #5096: RhoB and p53 cooperate to regulate the apoptotic response of UVB exposed human keratinocytes

Bruno Canguilhem, Anne Pradines, Alexis Peyret-Lacombe, Marie Charveron, Gilles Favre
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 5096.
Published: 01 May 2009
View article titled, Abstract #5096: RhoB and p53 cooperate to regulate the apoptotic response of UVB exposed human keratinocytes
Journal Articles

Loss of RhoB expression promotes migration and invasion of human bronchial cells

Emilie Bousquet, Julien MaziA?res, Gilles Favre, Anne Pradines
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3576.
Published: 01 May 2008
View article titled, Loss of RhoB expression promotes migration and invasion of human bronchial cells
Journal Articles

UVB induced RhoB expression controls apoptotic response in human keratinocytes

Bruno Canguilhem, Celine Boby, Caroline Baudouin, Anne Pradines, Marie Charveron, Gilles Favre
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1124–1125.
Published: 01 May 2005
View article titled, UVB induced RhoB expression controls apoptotic response in human keratinocytes
Journal Articles

Zoledronic acid impairs geranyl-geranylation but not farnesylation of small GTP-ases in prostatic cell lines

Sophie Séronie-Vivien, Marine Goffinet, Anne Pradines, Isabelle Lajoie-Mazenc, Jean-Charles Faye
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1099.
Published: 01 April 2004
View article titled, Zoledronic acid impairs geranyl-geranylation but not farnesylation of small GTP-ases in prostatic cell lines
Journal Articles

GGTI-298 Induces G0-G1 Block and Apoptosis Whereas FTI-277 Causes G2-M Enrichment in A549 Cells

Karine Miquel, Anne Pradines, Jiazhi Sun, Yimin Qian, Andrew D. Hamilton, Saïd M. Sebti, Gilles Favre
Journal: Cancer Research
Cancer Res (1997) 57 (10): 1846–1850.
Published: 01 May 1997
View article titled, GGTI-298 Induces G<sub>0</sub>-G<sub>1</sub> Block and Apoptosis Whereas FTI-277 Causes G<sub>2</sub>-M Enrichment in A549 Cells
Open the PDF for GGTI-298 Induces G<sub>0</sub>-G<sub>1</sub> Block and Apoptosis Whereas FTI-277 Causes G<sub>2</sub>-M Enrichment in A549 Cells in another window